‘Unwelcome and unsafe’: Why Japanese companies are retreating from China at a record pace

Japanese companies operating in China fell to 10,118 as of June, a record low: down 22% from June 2024 and about 30% from the 2012 peak. Over the past two years, 4,137 Japanese companies withdrew, while only 1,221 entered, as diplomatic tensions, tariff risks, rising costs and competition accelerated efforts to reduce China exposure. Topix-listed companies’ estimated China profit share fell below 15% so far this year from 23% in 2020, while the U.S. share rose to 35% from 25%.

Analysis

This is a slow-moving footprint-allocation signal, not yet evidence of a broad earnings shock: company counts say little about the assets, capacity or revenue being moved. The first-order winners are Chinese competitors in segments where Japanese firms retreat; over 6–18 months, India and U.S. manufacturing ecosystems could gain orders and investment, but only where suppliers, labor and infrastructure can absorb relocated production. Japanese automakers and parts suppliers face the clearest exposure, while precision and medical-equipment firms with strong local positioning are less vulnerable. A second-order risk is that firms diversify final assembly without diversifying critical-mineral inputs, leaving them exposed to Chinese export controls while incurring duplicated supply-chain costs.

Near term, the main market effect is a risk premium on China-dependent Japan exposure, not a uniform downgrade to Japanese equities. Over 1–3 months, watch company-level China revenue, capex plans, impairment charges and supplier orders; the headline count is not a substitute. Over 6–18 months, actual capacity transfers could benefit India/U.S. industrial ecosystems, but the investment and qualification cycle limits near-term earnings capture. The contrarian point: exits may be concentrated among smaller or less competitive operators, while firms able to localize can remain; broad “Japan wins, China loses” positioning risks overstating the shift. A thaw in relations, improved China demand, or evidence that closures have little capacity impact would weaken the thesis; broader mineral restrictions would strengthen the downside risk for Japan-linked production.

Key Decisions for Investors

• Avoid a broad short of Japanese equities on this data alone. Treat it as a watch item and screen automakers, parts suppliers and export-oriented manufacturers for China revenue, local production capacity, and impairment exposure before sizing a position.
• Consider a conditional relative-value position: long India-focused manufacturing beneficiaries versus a basket of Japan-listed China-dependent auto/parts firms, only after confirming actual new orders, transferred capacity and company-level exposure. Keep sizing modest; relocation benefits are likely delayed and may be offset by duplicated costs.
• Prefer a selective rather than blanket China short: monitor domestic competitors in segments where Japanese firms exit, but require evidence of share gains or guidance revisions. Localization by Japanese precision and medical-equipment firms could limit the addressable opportunity.
• Use Chinese export-control announcements and Japanese company disclosures as catalysts. Reassess if firms report material China-linked impairments or reduced guidance; conversely, evidence that exits involve low-capacity entities or that mineral restrictions ease would falsify the bearish Japan-exposure thesis.